Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 9,736 shares, a growth of 60.3% from the September 15th total of 6,075 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 4,314,053 shares, the short-interest ratio is presently 0.0 days.
Alaunos Therapeutics Trading Up 20.6%
Alaunos Therapeutics stock traded up $0.45 during midday trading on Friday, hitting $2.63. The stock had a trading volume of 32,000,035 shares, compared to its average volume of 19,045,854. Alaunos Therapeutics has a 52-week low of $0.72 and a 52-week high of $4.50. The company has a market capitalization of $6.68 million, a PE ratio of -1.38 and a beta of -0.87. The firm’s fifty day moving average is $1.52 and its two-hundred day moving average is $2.09.
Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Alaunos Therapeutics currently has an average rating of “Sell”.
View Our Latest Research Report on Alaunos Therapeutics
About Alaunos Therapeutics
Alaunos Therapeutics, Inc is a biotechnology company focused on developing genetically engineered T-cell therapies for the treatment of cancer, particularly solid tumors. Its research centers on T-cell receptor (TCR) therapies, which are designed to equip a patient’s immune cells to recognize and attack tumor-specific targets.
The company’s development programs have included TCR-T candidates directed at cancer-associated antigens such as NY-ESO-1 and LAGE-1a. Alaunos has also worked on a TCR library approach intended to support the development of personalized therapies targeting tumor mutations.
Further Reading
- Five stocks we like better than Alaunos Therapeutics
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
